EGFR and lung adenocarcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are widely used to treat lung adenocarcinomas, especially in non-small cell lung cancer (NSCLC), with EGFR-activating mutations [20,21].